Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
There are an estimated 1.3 billion smokers worldwide, and nearly six million people die from tobacco-related diseases each year. This article discusses smoking cessation drugs that are in development or on the market, and provides an outlook for their commercial potential.
Mike Yeadon discusses the challenges of starting a company based on assets licensed from Pfizer following the closure of its research operations in Sandwich, UK.